CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease OnsetJong‐Min Lee, Richard H. Myers, Ricardo Mouro Pinto et al.|Cell|2019Cited by 558
Guidelines and standards for the study of death and recalled experiences of death––a multidisciplinary consensus statement and proposed future directionsSam Parnia, Tara Keshavarz Shirazi, Stephen G. Post et al.|Annals of the New York Academy of Sciences|2022Cited by 67
Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosisRachael I. Scahill, Sarah J. Tabrizi, Mena Farag et al.|Nature Medicine|2025Cited by 53
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical TrialMichael Brownstein, Stephanie Lowenhaupt, Neal G. Simon et al.|Journal of Clinical Medicine|2020Cited by 32
Brain Structural Features of Myotonic Dystrophy Type 1 and their Relationship with CTG RepeatsEllen van der Plas, Peg Nopoulos, Mark Hamilton et al.|Journal of Neuromuscular Diseases|2019Cited by 30